Cannabis Science Prepares Release of Second Cannabis-Extract-Based Formulation Along with Official Facebook & Twitter Page Re...
November 09 2011 - 1:47PM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech
company developing pharmaceutical cannabis products, is pleased to
announce the preparation to release of the second Cannabis Science
brand formulation. The Company has been receiving a constant flow
of inquires via its website, emails, and telephone calls for
cannabis-extract based medicines. For example, cancer patients
seeking extract-based formulations for topical or internal use have
frequently contacted Cannabis Science. Manufacturing and packaging
is being completed for release through Colorado state licensed
dispensaries.
In light of the accumulating anecdotal reports of the successful
cancer treatments with cannabis extracts, the Company will continue
to keep patients updated on current peer-reviewed scientific
literature supporting the historical and modern use of cannabis to
treat "tumors”. Unlike conventional treatment, cannabis medicines
have an outstanding safety profile allowing patients in states with
medical marijuana laws to safely make informed decisions to legally
self-administration of various cannabis-based preparations.
The second Cannabis Science Brand extract-based formulation is
comprised of high quality extracts packaged in oral dispensing
syringes for patient self-administration for treatment. This is a
critical milestone for the Company in bringing its second
formulation to market. Other formulations will be made available
soon to medical marijuana patients in Colorado and other legal
medical marijuana states, such as California through select
California State licensed dispensaries. The Company’s intent is to
work with specially appointed legal providers and laboratories to
expand the availability of its formulations across the United
States where legally available.
Dr. Robert Melamede, Ph.D., the Company’s CEO, said, “We hear
from so many people wanting a reliable, high-quality formulation
that they can self-administer to treat a wide variety ailments. A
quality, standardized formulation is essential for long term care.
Initially, we have chosen two State licensed facilities in Colorado
to work with, both of the facilities were chosen for the quality of
their botanicals and patient care. We are looking forward to
expanding availability to other facilities in legal medical
marijuana States, specifically California, along with an increased
multiple formulation offerings.”
Social Network
Please visit
http://www.facebook.com/pages/Cannabis-Science/216643278395932
Please visit http://twitter.com/#!/CannabisScienc1
At the same time Cannabis Science is proud to announce the
release of their social network pages on Facebook and Twitter.
Facebook has over 250 million global users and over 600 million
visitors half of which visit more than once a day.* Twitter has
over 175 million* and has become a powerful media and marketing
resource especially for a global company like Cannabis Science.
In reference to the social networks Dr. Robert Melamede said
“One of our current goals at Cannabis Science is to increase
communication and exposure on a global scale of the Cannabis
Science mission to alleviate suffering and promote health
through cannabinoid science. Facebook and Twitter are not only the
resource but the catalyst.”
Dr. Melamede continued, “Cannabis Science Facebook and Twitter
pages are an information resource in regards to the company and
their operations. There will be updates on our first and second
cannabis-extract-based formulations. More importantly, these pages
will document how Cannabis Science is moving forward. Patients,
medical professionals and all those interested in the scientific
side of the medical cannabis industry can follow us and be included
in the global conversation. We hope this conversation includes
testimonials of people successes, tracks different patients ideas
and possible product releases for different ailments. The ultimate
goal of these Facebook and Twitter sites is to be a call to the
world that includes discussion from patients and to have this
conversation mature into a support campaign for the FDA.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The Company works
with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
*Source Twitter API page, Business Insider, March 31, 2011
Nicholas Carlson